HLS Therapeutics Inc. (OTCMKTS:HLTRF – Get Free Report)’s stock price dropped 2.1% during mid-day trading on Tuesday . The stock traded as low as $3.35 and last traded at $3.35. Approximately 100 shares changed hands during mid-day trading, a decline of 86% from the average daily volume of 736 shares. The stock had previously closed at $3.4220.
HLS Therapeutics Price Performance
The firm has a 50 day simple moving average of $3.26 and a 200-day simple moving average of $3.39.
About HLS Therapeutics
HLS Therapeutics is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription products for niche therapeutic markets. Headquartered in Mississauga, Ontario, the company builds its portfolio through strategic licensing agreements and in-house development, with an emphasis on therapies that address unmet needs in neurology and rare disorders.
The company’s marketed offering includes treatments for neurological conditions, most notably primary periodic paralysis, for which it commercializes dichlorphenamide (Keveyis) in North America.
Featured Stories
- Five stocks we like better than HLS Therapeutics
- Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending
- As Small-Cap Outperformance Continues, These 2 ETFs Provide Exposure
- Silicon Shake-Up: The AI Trade Is Moving Beyond NVIDIA
- The Silver Lining of Last Week’s Hims & Hers Earnings Miss
Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
